Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Ramucirumab in Neoadjuvant Stage IB-IIIA NSCLC
NCT04040361Phase 2Active, not recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Nov 2019
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, ramucirumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Center Hospital East. Started Nov 2019; status: active, not recruiting.
02
Drugs
pembrolizumabramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04040361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040361.